

News Release
FOR IMMEDIATE RELEASE
5 February, 2015

FOR MORE INFORMATION
Julie-Ann Cabana
(913) 304-4505
icabana@vinceandassociates.com



Vince & Associates Clinical Research Qualified as Early Phase Provider for Clinical Evaluation of Thorough QT

Overland Park, Kansas - Vince & Associates Clinical Research, a premier provider of early phase clinical research services, announced today it has become the first "iCardiac Certified Site." iCardiac is a major provider of cardiac safety services.

As a qualified partner, Vince & Associates and iCardiac will work together to provide biopharmaceutical clients with recommendations concerning the design, conduct, analysis and interpretation of clinical studies to assess the potential of a drug to delay cardiac repolarization during the conduct of a Phase I study.

"Vince & Associates is an organization that embodies dedication to superb quality and study execution, and is also a leader in implementing new scientific tools and approaches," said Alex Zapesochny, President & CEO of iCardiac Technologies. "We are very proud that Vince & Associates has become an iCardiac Certified Site and look forward to working closely with them to help sponsors more effectively assess the cardiac safety profiles of their drugs."

This partnership combines the expert early clinical pharmacology services from Vince & Associates Clinical Research with iCardiac's advanced cardiac safety technology. This expertise allows sponsors to assess arrhythmia liability earlier in drug development as an alternative approach to the current ICH E14 guidance. The ICH E14 guidance currently requires a separate study in healthy normal volunteers powered to statistically evaluate the potential of a new chemical entity (NCE) to prolong the QT interval.

Dr. Brad Vince, CEO and Medical Director of Vince & Associates Clinical Research expressed, "By working with iCardiac's High Precision QT analysis method with modern exposure modeling, Vince & Associates can help sponsors achieve statistically significant power in early phase studies without the need to expand the sample size. This approach has the potential to alleviate the requirement of conducting an expensive TQT study. More importantly, having this data earlier will provide our clients the ability to de-risk their programs and quickly decide to continue development or move forward with other drug candidates."

About Vince & Associates Clinical Research

Vince & Associates Clinical Research has provided clinical research services to the biopharmaceutical industry for 15 years. The research professionals at Vince & Associates are proud to be recognized in the industry as a “Center of Research Excellence.”

Vince & Associates currently operates a state-of-the-art, multimillion-dollar, 100 bed clinical pharmacology unit that combines the ultimate in subject safety and luxury. This early development unit has the upscale atmosphere necessary for the recruitment and retention of study volunteers in both short and long-term clinical trials. From the safety and security of the controlled access unit to the added features of a movie theater and game rooms, no detail has been overlooked.

About Altasciences

Altasciences is the parent company of wholly owned subsidiaries Vince & Associates Clinical Research (Kansas, USA) and Algorithme Pharma (Quebec, Canada and North Dakota, USA). Both organizations provide comprehensive early stage clinical services in Phase I/IIa, including the necessary support services in this critical stage of drug development.

More Information

Additional background materials pertaining to Vince & Associates Clinical Research are located on the corporate website at www.vinceandassociates.com.

#